SCHEMBL1099996

SCHEMBL1099996

O=S(=O)(c1ccccc1)N(CC(F)F)c1sc2ccccc2c1Br

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 4/20 0.37
NFE2L2 Q16236 4/20 0.37
TRPM8 Q7Z2W7 3/20 0.37
BACE1 P56817 3/20 0.37
KDM4E B2RXH2 3/20 0.37
LMNA P02545 3/20 0.37
MAPT P10636 2/20 0.37
HPGD P15428 2/20 0.37
MEN1 O00255 2/20 0.37
HTT P42858 2/20 0.37
KMT2A Q03164 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
GAA P10253 1/20 0.37
PTGS2 P35354 2/20 0.34
APOBEC3G Q9HC16 1/20 0.34
POLB P06746 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
TP53 P04637 1/20 0.34
HSD11B1 P28845 1/20 0.33
RECQL P46063 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1100682 0.90 TRPM8 (0.49) KEAP1NFE2L2TRPM8MEN1KMT2A
SCHEMBL1099086 0.85 TRPM8 (0.50) KEAP1NFE2L2TRPM8BACE1KDM4E
SCHEMBL1098976 0.84 BACE1 (0.45) KEAP1NFE2L2BACE1KDM4ELMNA
SCHEMBL1098979 0.84 BACE1 (0.45) KEAP1NFE2L2BACE1KDM4ELMNA
SCHEMBL1099466 0.84 HDAC6 (0.33) TRPM8LMNAMAPTHPGDKMT2A
SCHEMBL1098799 0.83 C1R (0.44) KEAP1NFE2L2TRPM8KMT2AHSD11B1
SCHEMBL1099374 0.82 TSHR (0.36) MAPTHTTPTGS2
SCHEMBL1098790 0.82 TRPM8 (0.47) KEAP1NFE2L2TRPM8LMNAMEN1
SCHEMBL1099577 0.81 RORC (0.48) KEAP1NFE2L2TRPM8MAPTHSD11B1
SCHEMBL1097407 0.80 KEAP1 (0.37) KEAP1NFE2L2TRPM8KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 KEAP1 2521/4885NFE2L2 2965/4885TRPM8 1/4885
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 KEAP1 2521/4885NFE2L2 2965/4885TRPM8 1/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 KEAP1 2521/4885NFE2L2 2965/4885TRPM8 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.